Shares of Onxeo were down more than 50 percent after the company’s Phase III liver cancer drug Livatag failed to improve survivability over standard of care.
Alexion Pharmaceuticals announced plans to cut costs by closing several sites, moving its headquarters and laying off 20 percent of staff. The job cuts follow 210 layoffs in March 2017.
Novartis AG’s biosimilar rituximab to treat blood cancers and immunological diseases such as rheumatoid arthritis was accepted for review by the U.S. FDA.
A groundbreaking deal between Allergan Plc and a Native American tribe to shield the company’s patents in administrative proceedings could also be used be to protect them from challenges in federal court, legal experts said, potentially dealing a blow to generic competition.
London-listed drugmaker Shire successfully tested a new medicine that prevents attacks in patients with hereditary angioedema (HAE).
AbbVie announced positive top-line results from its Phase III clinical trial of upadacitinib (ABT-494) in moderate-to-severe rheumatoid arthritis patients.
The pharma landscape has significantly evolved in the last decade, especially when it comes to clinical trials.
Janssen Sciences Ireland UC, a Johnson & Johnson company, announced the decision to halt development of its hepatitis C treatment combination JNJ-4178.
Cancer doctors are widening the net for immunotherapy, a hot new class of drugs that enlist the body’s defenses in the fight against tumors.